Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/13426
|
| Title: | Development of engineered cartilage product from bone marrow mesenchymal stem cells: An example in Taiwan |
| Authors: | Chen, YC;Liu, HC;Lin, FH;Chang, CH |
| Contributors: | Institute of Biomedical Engineering and Nanomedicine |
| Abstract: | Cartilage can redistribute human body's daily loads and decrease the friction force in the diarthrodial joints. However, it may be injured due to trauma, sports injury, biomechanical imbalance, and genetic disease. Microfracture (MF), osteochondral autograft transplantation (OAT), and autologous chondrocyte implantation (ACI) are the most common treatment procedures in the hospital. Recently, the concept of tissue engineering involving the combination of cells, scaffolds, and bioactive signals has inspired researchers. Our team of researchers synthesized a tri-copolymer from biological polymer by using gelatin, chondroitin-6-sulfate, and hyaluronic acid through cross-linking reaction. Lacuna formation could be seen in the tri-copolymer surrounding the chondrocytes, and some newly formed glycosaminoglycan was found in the engineered cartilage. Considering the dedifferentiation possibility of chondrocyte, bone marrow mesenchymal stem cells (BMSCs) become an ideal cell source for cartilage tissue regeneration, since they can be easily harvested from adult tissue, and be expanded in vitro. In an in-vivo porcine pilot study, the results showed that the defect site could be regenerated by BMSCs/collagen gel, and is formed with fibro/hyaline mixed cartilage tissue after implantation for six months. Several clinical studies using BMSCs for cartilage defect treatment were also conducted recently; clinical outcomes such as IKDC, Lysholm, and Tegner scores improved when the cartilage defects were repaired by several millions of mesenchymal stem cells, and there is no tumor formation after being treated with BMSCs during the 10-year follow-up. Moreover, recently a commercial BMSCs/collagen gel composite for cartilage repair was developed in Taiwan and clinical trial was conducted in 2008; the results showed that there is an improvement in IKDC and MRI scores during the nine-year follow-up. It seems that using an engineered cartilage made from BMSCs/collagen gel for cartilage defect treatment is a promising method. |
| Date: | 2021-03 |
| Relation: | Journal of Musculoskeletal Research. 2021 Mar;24(1):Article number 2130001. |
| Link to: | http://dx.doi.org/10.1142/S0218957721300015 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85103554237 |
| Appears in Collections: | [林峯輝] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| SCP85103554237.pdf | | 3829Kb | Adobe PDF | 213 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
